期刊
CLINICAL INFECTIOUS DISEASES
卷 47, 期 12, 页码 1587-1592出版社
OXFORD UNIV PRESS INC
DOI: 10.1086/593310
关键词
-
资金
- National Institute of Allergy and Infectious Diseases, National Institutes of Health
- US Food and Drug Administration
- US Department of Health and Human Services
Twenty years of global polio eradication efforts may soon eliminate the transmission of wild-type poliovirus. However, new information that has been learned about poliovirus, as well as the political realities of a modern world, demand that universal immunity against poliomyelitis be maintained, even after wild-type poliovirus is eradicated. Although 2 excellent vaccines have proven to be highly effective in the past, neither the live-attenuated vaccine nor the currently used inactivated vaccine are optimal for use in the posteradication era. Therefore, concerted efforts are urgently needed to develop a new generation of vaccine that is risk-free and affordable and can be produced on a global scale. Here, we discuss the desired properties of a vaccine and methods to create a new polio vaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据